Small-cell lung cancer is an aggressive tumor type with limited therapeutic options and poor prognosis. It is worthy to explore the new treatment pattern in consideration of the rapid disease progression. Therefore, this study aims to explore the effectiveness and safety of camrelizumab combined with chemotherapy and apatinib in the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).
In this Ⅱ study, 40 patients with pathological diagnosis of ES-SCLC who haven’t received prior systemetic therapy plan to be enrolled. The enrolled patients receive camrelizumab (200 mg, iv, q3w) combined with etoposide (80-100 mg/m2, iv, q3w, 4-6 cycles) and platinum drugs (selected by the researcher according to the patients, iv, q3w, 4-6 cycles) followed by maintenance with camrelizumab and apatinib (250 mg, QD). The primary endpoint is 6-month progress-free survival (6-month PFS) rate. Secondary endpoints are objective response rate (ORR), disease control rate (DCR), progression-free survival, overall survival and safety.
Up to September 17, 2022, 13 patients with a median age of 63 years were enrolled. The median treatment duration was 105 days. Among them, 13 patients were available for efficacy analysis, of which 10 patients achieved partial response, and 1 had stable disease. The 6-month PFS rate in evaluable patients was 54.55% (6/11). The ORR was 76.92% and DCR was 84.62%. The adverse reactions included reduction of proteinuria (23.0%), hemoptysis (8.0%), hypothyroidism (8.0%), abnormal liver function (38.0%), skin-related adverse reactions (38.0%), nausea (92.0%), fatigue (8.0%), lymphopenia (15.0%), leukopenia (15.0%) and anemia (54%). During the course of therapy, the majority of reported adverse events were grade 1-2 in severity. Of the 13 patients, only 1 patient experienced grade 3 treatment-related adverse event (anemia). All the adverse events can be controlled and alleviated after symptomatic treatment.
Camrelizumab in combination with chemotherapy and apatinib provided significant benefit and controllable security, supporting this combination as a new first-line treatment option for this population.
ChiCTR2100046355.
The authors.
Has not received any funding.
All authors have declared no conflicts of interest.